•
Jan 31, 2024

Donaldson Q2 2024 Earnings Report

Reported record sales and earnings, driven by volume growth and pricing benefits.

Key Takeaways

Donaldson reported a strong second quarter with sales up 5.8% to $876.7 million and EPS of $0.81, a 15.9% increase compared to the previous year. The company is raising its fiscal 2024 operating margin and EPS guidance and is on track to deliver record full-year sales and EPS.

Second quarter sales increased by 5.8% to $876.7 million compared to 2023.

GAAP EPS increased by 15.9% to $0.81 compared to 2023.

Gross margin was 35.2%, up 90 basis points from 34.3% in 2023.

The company is raising fiscal 2024 operating margin and EPS guidance.

Total Revenue
$877M
Previous year: $828M
+5.8%
EPS
$0.81
Previous year: $0.75
+8.0%
Operating Margin
14.8%
Previous year: 14%
+5.7%
Gross Margin
35.2%
Previous year: 34.3%
+2.6%
Effective Tax Rate
23.5%
Previous year: 24.1%
-2.5%
Gross Profit
$309M
Previous year: $284M
+8.5%
Cash and Equivalents
$194M
Previous year: $179M
+8.0%
Free Cash Flow
$65.7M
Previous year: $72.8M
-9.8%
Total Assets
$2.78B
Previous year: $2.58B
+7.9%

Donaldson

Donaldson

Forward Guidance

Full-year EPS is forecast to be between $3.24 and $3.32. Sales are expected to increase between 3% and 7% year over year. Operating margin is expected to improve to between 15.0% and 15.4%.

Positive Outlook

  • Full-year EPS is forecast to be between $3.24 and $3.32, up from prior guidance of between $3.14 and $3.30.
  • Sales are expected to increase between 3% and 7% year over year, with a pricing benefit of approximately 2% and a currency translation tailwind of roughly 1%.
  • Mobile sales are forecast to increase between 1% and 5% versus 2023.
  • Industrial sales are expected to increase between 3% and 7% compared with prior year.
  • Life Sciences sales are forecast to grow approximately 20% year over year.

Challenges Ahead

  • Continued softening end-market conditions, including in the agriculture markets and in China, are expected to drive a low double-digit decrease in Off-Road sales.
  • On-Road sales are projected to be flat versus prior year.
  • Operating margin is expected to improve to between 15.0% and 15.4%, Year over year gross margin improvement is forecast to offset investments in the Life Sciences segment.
  • Interest expense is forecast to be approximately $23 million.
  • Donaldson projects a fiscal 2024 effective income tax rate of between 24% and 25%.